KDM2A抗体;KDM2A Antibody—艾普蒂 新品

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using P13395(KDM2A Antibody) at dilution 1/60. (Original magnification: ×200)    

  
  

The KDM2A antibody is a key tool for studying the lysine-specific demethylase 2A (KDM2A), an enzyme involved in epigenetic regulation. KDM2A, also known as FBXL11 or JHDM1A, belongs to the Jumonji C (JmjC) domain-containing histone demethylase family. It specifically demethylates histone H3 on lysine 36 (H3K36me2/me1), modulating chromatin structure and gene expression. KDM2A plays roles in diverse biological processes, including cell proliferation, differentiation, and genomic stability, and is implicated in cancer, stem cell biology, and aging.

The antibody targets KDM2A’s unique domains, such as its JmjC catalytic domain or N-terminal regions, enabling detection and functional analysis in assays like Western blotting, immunofluorescence, or chromatin immunoprecipitation (ChIP). Researchers use it to investigate KDM2A’s interactions with chromatin modifiers (e.g., Polycomb repressive complexes) or its localization to CpG islands, where it may suppress spurious transcription.

Validating KDM2A antibodies requires specificity testing via knockout controls, as cross-reactivity with homologous proteins (e.g., KDM2B) can occur. Commercial antibodies often cite applications in human, mouse, or rat samples. As KDM2A gains attention for its dual roles in tumor suppression and oncogenesis, its antibody remains critical for dissecting context-dependent mechanisms in disease models and therapeutic targeting.